ReNeuron Group PLC

ReNeuron Group PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)93.50
  • Today's Change0.00 / 0.00%
  • Shares traded43.07k
  • 1 Year change+15.43%
  • Beta1.8968
Data delayed at least 20 minutes, as of Dec 03 2021 15:05 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Key statistics

On Friday, ReNeuron Group PLC (RENE:LSE) closed at 93.50, 33.57% above the 52 week low of 70.00 set on Dec 16, 2020.
52-week range
70.00Dec 16 2020153.78May 06 2021
Previous close93.50
Average volume270.70k
Shares outstanding57.06m
Free float42.27m
P/E (TTM)--
Market cap53.35m GBP
EPS (TTM)-0.1854
Data delayed at least 20 minutes, as of Dec 03 2021 15:05 GMT.
More ▼

Investors Chronicle View

The last IC recommendation on ReNeuron Group PLC shares was Buy at 138.00 on 10 Dec 2019Read the full article

Board of Directors


Iain Ross, Chairman


Olav Hellebo, Chief Executive Officer


Barbara Staehelin, Senior Independent Non-Executive Director


Dr Tim Corn MSc FFPM FRCPsych, Non-Executive Director


Professor Sir Chris Evans OBE, Non-Executive Director


Mark Evans, Non-executive Director


Dr Mike Owen Ph.D, Non-Executive Director


Head Office:

Pencoed Business Park
CF35 5HY

General enquiries:

Product and licensing enquires:

An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.